Patrick Donnelly Analyst Performance

Managing Director, Equity Research at Citigroup

Patrick Donnelly is a stock analyst at Citigroup focused in the medical sector, covering 15 publicly traded companies. Over the past year, Patrick Donnelly has issued 22 stock ratings, including buy, hold, and sell recommendations. While full access to Patrick Donnelly's proprietary MarketBeat Analyst Ranking is reserved for MarketBeat All Access subscribers, the rating is updated daily to reflect the most recent analyst activity. This profile highlights Patrick Donnelly's coverage history, rating activity, and performance tendencies — helping individual investors make more informed trading decisions.

Analyst Ranking: Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating MarketBeat
Average Return: 00.00% 12-Month ROI
Success Rate: 00.00% Profitable Ratings
Total Ratings: 24 Last 3 Years
Buy Recommendations: 52.17% 12 Buy Ratings
Companies Covered: 15 Unique Companies

Ratings Distribution

Rating	Percentage	Count
Strong Buy	0.0%	0 ratings
Buy	52.2%	12 ratings
Hold	43.5%	10 ratings
Sell	4.3%	1 ratings

Out of 23 total stock ratings issued by Patrick Donnelly at Citigroup, the majority (52.2%) have been Buy recommendations, followed by 43.5% Hold and 4.3% Sell.

Best & Worst Calls

This analyst does not have any ratings with enough history to determine best and worst calls.

Exchange Coverage

Exchange	Percentage	Count
NYSE	53.3% of companies on NYSE	8 companies
NASDAQ	46.7% of companies on NASDAQ	7 companies

Patrick Donnelly, an analyst at Citigroup, currently covers 15 companies listed on NYSE and NASDAQ, with the majority traded on NYSE.

Coverage Focus

Sector Icon	Sector	Percentage
	Medical 13 companies	86.7%
	Transportation 1 company	6.7%
	Computer and Technology 1 company	6.7%

Patrick Donnelly of Citigroup specializes in stock coverage within the Medical sector, with additional focus on Transportation and Computer and Technology companies.

Coverage Industries

Industry	Percentage
MED INSTRUMENTS 4 companies	26.7%
MEDICAL SERVICES 3 companies	20.0%
MED - BIOMED/GENE 2 companies	13.3%
MED PRODUCTS 2 companies	13.3%
EQUIPMENT RENTAL & LEASING 1 company	6.7%
INSTRU - SCIENTFC 1 company	6.7%
MED - OUTP/HM CRE 1 company	6.7%
MEDICAL INFO SYS 1 company	6.7%

Timeframe

Start Date

End Date

Rating

12-Month ROIAll ROI

Export to Excel

Company	Report Date	Action	Report Date Price	12-Month Price Target	Rating
ICLR Icon	8/21/2025	Reiterated Rating	$180.25	$200.00	Neutral
TECH Bio-Techne	8/21/2025	Upgrade	$54.33	$70.00	Buy
MTD Mettler-Toledo International	8/21/2025	Boost Price Target	$1,302.25	$1,600.00	Buy
CAI CAI International	8/13/2025	Boost Price Target	$32.46	$42.00	Buy
QDEL QuidelOrtho	8/6/2025	Lower Price Target	$23.44	$40.00	Buy
BRKR Bruker	8/4/2025	Lower Price Target	$34.72	$38.00	Neutral
CAI CAI International	7/14/2025	Initiated Coverage	$26.51	$34.00	Buy
HOLX Hologic	7/9/2025	Upgrade	$64.90	$80.00	Buy
ILMN Illumina	7/9/2025	Downgrade	$99.27	$80.00	Strong Sell
BRKR Bruker	5/22/2025	Downgrade	$36.45	$40.00	Hold
BIO Bio-Rad Laboratories	5/2/2025	Lower Price Target	$236.83	$350.00	Buy
ICLR Icon	4/7/2025	Lower Price Target	$150.81	$215.00	Buy
BRKR Bruker	4/7/2025	Lower Price Target	$38.21	$50.00	Buy
DGX Quest Diagnostics	3/4/2025	Downgrade	$176.81	$185.00	Neutral
TMO Thermo Fisher Scientific	3/4/2025	Lower Price Target	$516.21	$570.00	Neutral
TXG 10x Genomics	3/4/2025	Lower Price Target	$10.32	$15.00	Buy
AVTR Avantor	3/4/2025	Lower Price Target	$15.53	$18.00	Neutral
TECH Bio-Techne	3/4/2025	Lower Price Target	$60.00	$70.00	Neutral
IQV IQVIA	3/4/2025	Lower Price Target	$183.94	$210.00	Neutral
TXG 10x Genomics	2/13/2025	Lower Price Target	$11.35	$20.00	Buy
TMO Thermo Fisher Scientific	1/31/2025	Boost Price Target	$598.16	$650.00	Neutral
DHR Danaher	1/30/2025	Lower Price Target	$223.16	$265.00	Buy

Stock Forecasts and Research Tools

Today's Ratings

Top-Rated Stocks

More Ratings Tools

Price Forecasts for Popular Stocks

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.